Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Stock Short Interest Rises 4,905.1%

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 919,936 shares, an increase of 4,905.1% from the September 30th total of 18,380 shares. Approximately 89.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 7,171,805 shares, the days-to-cover ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Trading Down 4.9%

Shares of BDRX traded down $0.18 during trading hours on Tuesday, hitting $3.51. 12,553 shares of the stock were exchanged, compared to its average volume of 227,136. Biodexa Pharmaceuticals has a fifty-two week low of $2.70 and a fifty-two week high of $357.60. The business has a 50-day moving average of $6.12 and a 200-day moving average of $27.81.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals plc, formerly known as Midatech Pharma plc, is a biopharmaceutical company focused on developing medicines for diseases with significant unmet medical needs. The company’s work has centered on oncology, rare diseases and conditions that are difficult to treat with conventional drug-delivery methods.

Biodexa’s development programs have included MTX110, a proprietary aqueous formulation of panobinostat being investigated for direct administration into brain tumors, including diffuse intrinsic pontine glioma.